Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

  title={Intraperitoneal cisplatin and paclitaxel in ovarian cancer.},
  author={Deborah K. Armstrong and Brian Bundy and Lari Wenzel and Helen Q Huang and Rebecca N. Baergen and Shashikant Lele and Larry J. Copeland and Joan L. Walker and Robert A. Burger},
  journal={The New England journal of medicine},
  volume={354 1},
BACKGROUND Standard chemotherapy for newly diagnosed ovarian cancer is a platinum-taxane combination. The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer. METHODS We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm to receive… CONTINUE READING
Highly Influential
This paper has highly influenced 51 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by